


Varicose Veins

Robert J. Beaulieu, MD, MSE
Assistant Professor, Vascular Surgery
The Ohio State University Wexner Medical Center




MedNet21
Center for Continuing Medical Education

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER



What are varicose veins?


- >3 mm dilatation of subcutaneous vein.

Author: Intermedicbox (CC BY 3.0)


Spider Veins
→
Varicose Veins
→
Venous Ulcer

Why do Varicose Veins Develop?



Blood Flowing In One Direction

Normal Vein



Blood Flowing In Both Directions

Swelling

Damaged Valve

Varicose Vein

Author: Blausen Medical Communications, Inc. (CC BY 3.0) - Link in final slide.

CEAP Classification System

- C: Clinical classification
- E: Etiologic classification
- A: Anatomic classification
- P: Pathophysiologic classification

CEAP: Clinical Classification System

- C1: Telangiectasia
- C2A: Asymptomatic Varicose Veins
- C2S: Symptomatic Varicose Veins
- C3: Edema
- C4: Skin or subcutaneous tissue changes
- C5: Healed Ulcer
- C6: Active Ulcer

CEAP: Clinical Classification System

- C1: Telangiectasia	
- C2A: Asymptomatic Varicose Veins	COSMETIC
- C2S: Symptomatic Varicose Veins	
- C3: Edema	
- C4: Skin or subcutaneous tissue changes	MEDICAL
- C5: Healed Ulcer	
- C6: Active Ulcer	

How can Varicose Veins be managed?

- Conservative Measures:
 - Weight loss
 - *Prevent Varicose Veins*
 - Reduce progression of varicose veins already present.
- Leg Elevation
- Compression Therapy
 - *20-30 Thigh-High Compression*
 - "The best compression is the one the patient will wear."

Medication Therapy for VV

- No well organized data about medications for VV in the US.
- Most press: Flavonoids
 - May have antiangiogenic property.
- Alternative Regimens
 - These are not proven and should be reviewed for interactions.
 - Horse Chestnut
 - Ginkgo Biloba
 - Grape (leaves or fruit)

Recent 2021 manuscript shows some potential for a combined formula.

Do Varicose Veins Cause DVT?

Original Investigation

FREE

February 27, 2018

Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease

Shyue-Luen Chang, MD^{1,2,3}, Yau-Li Huang, MD^{1,2,3}, Mei-Ching Lee, MD^{1,2,3}, et al.

> Author Affiliations | Article Information

JAMA. 2018;319(8):807-812. doi:10.1001/jama.2018.0246

- Recurrent or long segment SVT of VV → more aggressive treatment

Attributions:

Slide 3: IntermedichboFile:Ulcus cruris art.JPG - Wikimedia Commons

Slide 5: Blausen Medical Communications, Inc. File:Blausen 0891 VaricoseVein.png - Wikimedia Commons



Varicose Veins

Mounir J. Haurani, MD

Associate Professor of Surgery

Medical Director OSUMC, East, and OSOC Upper Arlington Vascular Labs

Division of Vascular Diseases and Surgery

The Ohio State University Wexner Medical Center

MedNet21

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

Invasive Treatment Options

- Intense Pulsed Light(IPL) or Topical LASER
- Sclerotherapy
- Phlebectomy
- High Ligation and Stripping
- Ablation (thermal and non-thermal)

IPL and Topical LASER

- Suitable for most patients with telangiectasia or matting from prior treatments
- No maximum dose per session (outside of pain tolerance)
- Advantages over needle based therapy
 - Needle-phobic patients
 - Resistant telangiectasia or matting
 - Patients prone to hyperpigmentation
 - Intolerance to sclerosants

Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy

GABRIEL IANOSI¹, SIMONA IANOSI², MADALINA XENIA CALBUREANU-POPESCU³,
CRISTINA TUTUNARU², DANIELA CALINA⁴ and DANIELA NEAGOE⁵

Departments of ¹Surgery and ²Dermatology, Medical Center Dr. Iancu, University of Medicine and Pharmacy of Craiova, 200000 Craiova; ³Department of Applied Mechanics and Civil Buildings, Faculty of Mechanics, University of Craiova, 200512 Craiova; ⁴Department of Pharmacology, University of Medicine and Pharmacy of Craiova; ⁵Department of Internal Medicine, Medical Center Dr. Iancu, University of Medicine and Pharmacy of Craiova, 200000 Craiova, Romania

Received August 13, 2008; Accepted September 24, 2008

DOI: 10.3892/etm.2018.6985

**In general, telangiectasias
1mm or smaller Laser works as
well as sclerotherapy, >1mm
sclerotherapy is more effective**

Attempts to randomize and compare sclerotherapy to Laser Challenges – blinding, assessment of discomfort



IPL and LASER - limitations


- Melanin will compete with hemoglobin at absorbing energy from Lasers
 - Use caution in darker skin
 - Avoid tanning and sun exposure before or after
- Skin needs constant cooling during treatment

Sclerotherapy

- Directly accessing the varicosity with a fine needle
- Injection of chemical compound to damage the vein
- Results in fibrosis of the vein
- Primarily used for small varicose veins and telangiectasias after underlying source of reflux treated, but can be used on saphenous vein and its tributaries


Sclerotherapy

- Can be liquid or foamed
 - Longer dwell time in the vein
 - More surface area covered
 - Easily visualized under ultrasound
 - Volume limited




Foam Sclerotherapy

- They produce endothelial damage
- Exposes collagen and leads to activation of platelets and clotting
- Thrombosis and inflammation leads to fibrosis of the vein
- Numerous (>15) randomized trials show similar short term efficacy vs traditional surgery for treatment of truncal reflux
- May be some increased recanalization long term vs traditional ablative methods



Microfoam Chemical Ablation

- In US Varithena™ is FDA approved
- Proprietary mix of gasses
- Smaller foam that is more stable
- Less risk of air embolism
- Not necessarily more effective than "home made"



HCPCS Code	Short Description	Non-Facility Price	Facility Price	Work RVU	Global
36465	Microfoam Chem Ablation 1 vein	\$1,420.94	\$120.52	2.35	0
36466	Microfoam Chem Ablation mlt vn	\$1,586.21	\$155.49	3.00	0
36470	Sclerotherapy 1 incmptnt vein	\$110.58	\$38.90	0.75	0
36471	Sclerotherapy mlt incmptnt vn	\$194.86	\$76.35	1.50	0

Foam Sclerotherapy


- Side effects most commonly are from localized phlebitis resulting in pain and nodules, hyperpigmentation.
- Serious complications are very rare
 - 0.5% muscular vein thromboses (1)
 - 0-1% with DVT (2)
 - 0.09%–4.5% with visual disturbances (3)
 - Stroke, arterial injection, MI all described but exceedingly rare, thought to be from PFO

1. Guex JJ, Schlegel DE, Otto J et al. The French poldocanol study on long-term side effects: A survey covering 3,357 patient years. Dermatol Surg 2010;36(Suppl. 2):993-1003.
 2. Gillet JL, Guedes JM, Guex JJ et al. Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: A controlled multicentre prospective study including 1,025 patients. Phlebology 2009;24:131-8.
 3. Wilkenberg T, Smith PC, Shepherd A, and Davies AH. Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: A systematic literature review. Phlebology 2012;28:123-31.

High Ligation and Stripping

- Largely historical
- Does not provide vastly superior results to ablation
- Has higher morbidity vs ablation so any advantage is lost
- 15-30% had recurrence because of neovascularization

- 1-Superficial inferior epigastric
- 2-Superficial circumflex iliac
- 3-Superficial antrolateral
- 4-Superficial external pudendal
- 5-Superficial posteromedial




Phlebectomy

- Like High Ligation and Stripping, tradition open phlebectomy not often done
- Uses large incisions, high morbidity
- Dr. Robert Muller in 1950-60's first performed and described modern "Ambulatory Phlebectomies" but adoption took decades
- Varicose veins removed as outpatient, under local anesthesia, with small punctures and hooks.
- Apply hemostatic compression to allow for immediate ambulation.
- AKA: Stab avulsion, stab phlebectomy, microphlebectomy, and microextraction



Ablation (Truncal Veins)

- "Heat based" ablative procedures have been used for >20 years
- Radiofrequency ablation (RFA) or Laser
- Minimally invasive
- Equal efficacy, decreased morbidity, improved recovery, better satisfaction.
- Leaves tributaries at SFJ to preserve the normal physiologic flow
- Less hemodynamic disturbance and therefore less neovascularization.



Ablation - Results

- 90-100% effective short to mid term
- 84% closed at 5 years, 92% remained reflux free
- The analgesic needed in the RF patients is < 600mg ibuprofen/day
- Return to work on average < 7 days

Ablation - Results

- A multicenter study from five centers in the United States and Europe (EVOLVE Study RFA vs Surgery)
 - less postoperative pain for up to 3 weeks
 - earlier return to activities/work (3days)
 - better cosmetic outcomes
 - 2-year follow-up showed continued improved QoL
- The RECOVERY study (RF versus EVLT)
 - RF had less pain, bruising, and better QoL in early post-operative period.
 - But not sustained at 30 days


- Lurie F, Creton D, Eklof B et al. Prospective randomized study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVE): Two-year follow-up. Eur J Vasc Endovasc Surg 2005;29(1):67-73.
- Almeida JJ, Kaufman J, Gökertiz O et al. Radiofrequency endovenous ClosureFAST versus laser ablation for the treatment of great saphenous reflux: A multicenter, single-blinded, randomized study (RECOVERY Study). J Vasc Interv Radiol 2009;20(6):752-9.

Ablation - Potential Complications

- Phlebitis
 - tender, erythematous, or ecchymosis
 - self-limiting
 - Similar rates in Laser and RFA (1-10%)
- Burns - rarely observed today
- Bruising - in RECOVERY study 2.2% of RFA
- Paresthesia in first generation studies were >5%, now rare

Ablation - Potential Complications

- Deep Vein Thrombosis
 - Mechanism different than typical postoperative thrombosis
 - Related to heat generated from catheters
 - With current generation devices, <1%
 - Endovenous Heat Induced Thrombosis (EHIT)
 - 3-7 days



Ablation - Limitations

- Previously scarred veins
- Larger than 2-2.5cm, or smaller than 2.5mm
- Tortuosity (maybe)
- Acute thrombus
- Extrafacial superficial vein

Non-Thermal Non-Tumescent Ablation

- Foam sclerotherapy or Microfoam Chemical Ablation
- Cyanoacrylate embolization (CAE)
- Mechanical Occlusion Chemically Assisted (MOCA)
- V-Block-assisted sclerotherapy (VBAS, minimal data available)
- Current limitations based on local markets and insurance

Non-Thermal Non-Tumescent Ablation

- Minimal risk of nerve or skin injury
- Safe below the knee
- Minimal discomfort to patients
- Disposable systems with lower capital equipment costs
- Patients can return to normal activity / work quickly

NTNT - MOCA

- Mechanism is both mechanical damage to the endothelium via 3500 RPM rotating wire and
- Unlike sclerotherapy, media is also damaged
- 96% closure rate at 1 and >2 years
- Minimal complications
 - No DVT, nerve, or skin damage.
- Venous Clinical Severity improved

Elias S, Lam YL, Wittens CHA. Mechanochemical ablation: status and results. *Phlebology*. 2013;28(1_suppl):10-14. doi:10.1177/0268355513477787

NTNT - CAE

- U.S. pivotal trial, VeClose is non-inferiority vs RFA
- 6-month occlusion rates were equivalent 99% vs 94%
- All measures of QoL were equal
 - procedural pain, bruising, and VCSS and 2 PRO measures

Morrison N, Gibson K, McEnroe S et al. Randomised trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). *J Vasc Surg Venous Lymphat Disord* 2015;4:485-94.

Summary

- Surgical management of symptomatic varicose veins must include investigation and treatment of underlying cause (truncal vein reflux)
- Treatment options depend on size and location of the veins
- Treatments can range from open surgical ones, to anesthetic free local procedures
- Treatment of GSV reflux results in short and long-term improved QoL regardless of the modern modality.